Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1801)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 25, 2025

Reference is made to the circular (the "**Circular**") of Innovent Biologics, Inc. (the "**Company**") incorporating, amongst others, the notice (the "**Notice**") of annual general meeting of the Company (the "**AGM**") dated June 3, 2025. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

All the Directors, namely Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors attended the AGM in person or by electronic means.

At the AGM held on June 25, 2025, all the proposed resolutions as set out in the Notice were duly passed by way of poll and the poll results were as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	**Against**
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of directors and the auditor of the Company for the year ended December 31, 2024	859,027,466 100.000000%	0 0.000000%
2(i).	To re-elect Dr. De-Chao Michael Yu as an executive Director	830,097,538 96.824480%	27,224,428 3.175520%
2(ii).	To re-elect Dr. Charles Leland Cooney as an independent non-executive Director	851,533,665 99.129638%	7,476,498 0.870362%
2(iii).	To re-elect Mr. Gary Zieziula as an independent non-executive Director	857,548,535 99.832884%	1,435,500 0.167116%
3.	To authorise the Board to fix the remuneration of the Directors	852,989,016 99.297060%	6,038,450 0.702940%
4.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the Board to fix their remuneration	854,755,151 99.502657%	4,272,315 0.497343%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
5.	To grant a general mandate to the Directors to buy back shares of the Company (excluding any shares that are held as treasury shares, if any)	858,467,966 99.934868%	559,500 0.065132%
6.	To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company (excluding any shares that are held as treasury shares, if any)	679,333,796 79.082146%	179,689,170 20.917854%
7.	To extend the general mandate granted to the Directors to issue shares of the Company by adding thereto the total number of the shares to be bought back by the Company (excluding any shares that are held as treasury shares, if any)	607,212,865 70.686083%	251,814,601 29.313917%
8.	To approve the grant of 2,754,000 restricted shares to Dr. De-Chao Michael Yu on March 28, 2025 in accordance with the terms of the share incentive scheme adopted by the Company on June 21, 2024	625,986,190 82.724320%	130,727,418 17.275680%

As more than 50% of votes were cast in favor of the ordinary resolutions nos. 1 to 8 above, all such resolutions were duly passed by the Shareholders as ordinary resolutions.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
June 25, 2025

Notes:

(a) As at the date of the AGM, the total number of shares of the Company in issue was 1,653,402,392 shares.

(b) The total number of shares of the Company entitling the holders to attend and vote on the resolutions at the AGM was 1,653,402,392 shares.

(c) As at the date of AGM, Dr. Yu and his associates, control the voting rights in respect of an aggregate of 109,081,025 Shares. Dr. Yu and his associates were required to and had abstained from voting on the above proposed resolutions numbered 2(i) and 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(d) As at the date of AGM, Mr. Ronald Hao Xi Ede and his associates control the voting rights in respect of an aggregate of 3,716,099 Shares. Mr. Ede and his associates were required to and had abstained from voting on the above proposed resolution numbered 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(e) As at the date of AGM, Ms. Qian Zhang and her associates control the voting rights in respect of an aggregate of 794,977 Shares. Ms. Zhang and her associates were required to and had abstained from voting on the above proposed resolution numbered 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(f) As at the date of AGM, Dr. Charles Leland Cooney and his associates control the voting rights in respect of an aggregate of 56,393 Shares. Dr. Cooney and his associates were required to and had abstained from voting on the above proposed resolutions numbered 2(ii) and 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(g) As at the date of AGM, Ms. Joyce I-Yin Hsu and her associates control the voting rights in respect of an aggregate of 17,303 Shares. Ms. Hsu and her associates were required to and had abstained from voting on the above proposed resolution numbered 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(h) As at the date of AGM, Mr. Gary Zieziula and his associates control the voting rights in respect of an aggregate of 43,431 Shares. Mr. Zieziula and his associates were required to and had abstained from voting on the above proposed resolutions numbered 2(iii) and 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(i) As at the date of AGM, Mr. Shuyun Chen and his associates control the voting rights in respect of an aggregate of 14,183 Shares. Mr. Chen and his associates were required to and had abstained from voting on the above proposed resolutions numbered 8 in relation to the Grant to Dr. Yu at the AGM in accordance with the Listing Rules on the Stock Exchange.

(j) Saved as disclosed above, there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules.

(k) Saved as disclosed above, no shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM.

(l) Save as disclosed above, no parties have stated their intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

(m) The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

(n) The full text of the above resolutions are set out in the AGM Notice.

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors.